We tried something silly: we asked AI to adapt the lyrics of a familiar seasonal tune as a playful ode to zebrafish behavior analysis. Check out this post's image for the lyrics. #DrugDiscovery #Biodefense #AIinDrugDiscovery

Join Lunai Bioworks at the Biotech Showcase during JPM 2026 in San Francisco (Jan 12-15). Gabe Musso, Chief Scientific Officer at BioSymetrics (a Lunai Bioworks company), will be representing our team. Let’s connect. #JPM #BiotechShowcase #AI

Parkinson's isn't just one disease. Lunai Bioworks and BioSymetrics used Augusta to identify three PD subtypes and prioritized drug targets that link patients to proteomic signatures, creating a foundation for future development. #ParkinsonsDisease #PrecisionMedicine #Proteomics

Gabe Musso, Chief Scientific Officer at BioSymetrics (a @lunaibioworks.com company), is joining the AI Technology panel at the 24th ICMLA conference in Boca Raton on December 4 at 6:30 p.m. Join the conversation on applied AI. #AI #MachineLearning #ICMLA2025

Lunai Bioworks has secured a licensing LOI for our DCCT platform after seeing complete regression of pancreatic tumors in humanized models. #cancerimmunotherapy #pancreaticcancer #celltherapy

Gabe Musso (CSO, BioSymetrics, a @lunaibioworks.com company) will speak at PMWC 2026 Silicon Valley on Mar 6 with a talk titled “Closing the Loop: Coupling AI with In Vivo Validation.” #PMWC2026 #AIDrugDiscovery #AIinMedicine

In a recent webinar hosted by The Michael J. Fox Foundation Data Community of Practice, Victoria Catterson shared how our team uses phenoclustering on PPMI data to uncover Parkinson's disease subtypes and new biomarker leads. #ParkinsonsDisease #Proteomics #PPMI

We’ve published a Brief Report in Vaccines on our second‑generation, clinical‑grade allogeneic DC therapy. In humanized pancreatic cancer models, it achieved complete regression of primary and metastatic tumors. #PancreaticCancer #ImmunoOncology #CellTherapy

We’re using AI and zebrafish data to help detect neurotoxic compounds targeting acetylcholinesterase (AChE) and support defense and public health. #Biodefense #Neurotoxicity #AChE

We are proud to announce that BioSymetrics (a @lunaibioworks.bsky.social company), Leiden University Medical Center, and @ufresearch.bsky.social have co-authored a new Nature Communications study identifying serum proteins that predict disease progression in Duchenne muscular dystrophy (DMD).

We’re partnering with Moleculera Biosciences to detect Alzheimer’s years before symptoms appear. Using AI-driven analytics with novel neuroinflammatory biomarkers, we’re shifting diagnostics from reactive to proactive. #EarlyDetection #PrecisionMedicine #Alzheimers

Hello! 👋 We’re Lunai Bioworks. Decoding life. Discovering cures. Our AI-powered phenomics platform captures disease in motion, decoding biology at scale to bring clarity to complexity.